Pfizer Obtains Preliminary Injunction Against Teva/Ranbaxy Accupril Generic
Executive Summary
A preliminary injunction halting the sale of generic versions of Pfizer's Accupril (quinapril)may be a discouraging sign for generic companies considering "at risk" launches
You may also be interested in...
Teva Launches Generic Allegra “At Risk” Under Barr’s Exclusivity
Barr could take a one-time charge this quarter for estimated liability related to Teva's "at risk" launch of generic Allegra under Barr's exclusivity
Teva Launches Generic Allegra “At Risk” Under Barr’s Exclusivity
Barr could take a one-time charge this quarter for estimated liability related to Teva's "at risk" launch of generic Allegra under Barr's exclusivity
Declaratory Judgment Ruling Will Add Uncertainty To Generic Launches
Generic companies are likely to face an increased threat of patent infringement lawsuits on the eve of launch following an appeals court ruling on the standards for seeking a declaratory judgment of noninfringement